Challenges to Value-Enhancing Innovation in Health Care Delivery
Commonalities and Contrasts with Innovation in Drugs and Devices
Download
Download eBook for Free
Full Document
| Format | File Size | Notes |
|---|---|---|
| PDF file | 0.3 MB | Use Adobe Acrobat Reader version 10 or higher for the best experience. |
Summary Only
| Format | File Size | Notes |
|---|---|---|
| PDF file | 0.1 MB | Use Adobe Acrobat Reader version 10 or higher for the best experience. |
Purchase
Purchase Print Copy
| Format | List Price | Price | |
|---|---|---|---|
| Add to Cart | Paperback50 pages | $18.00 | $14.40 20% Web Discount |
Limiting the growth of health care costs while improving population health is perhaps the most important and difficult challenge facing U.S. health policymakers. The role of innovation in advancing these social goals is controversial, with many seeing innovation as a major cause of cost growth and many others viewing innovation as crucial for improving the quality of care and health outcomes. The authors argue that mitigating the tension between improving health and controlling costs requires more-nuanced perspectives on innovation. More specifically, they argue that policymakers should carefully distinguish between innovative activities that are worth their social costs and activities that are not worth their social costs and try to encourage the former and discourage the latter. The paper considers innovation in drugs, devices, and methods of delivering health care, with particular attention to delivery.
Table of Contents
Chapter One
Introduction
Chapter Two
Stages of Innovation and Defining Health Care Innovation
Chapter Three
Cross-Cutting Conceptual Perspectives
Chapter Four
The "Value Chasm"
Chapter Five
Social Value in Drug and Device Innovation
Chapter Six
Delivery Innovation and Social Value
Chapter Seven
Conclusion
The research described in this report was sponsored by RAND Health's Comprehensive Assessment of Reform Efforts (COMPARE) and the Ewing Marion Kauffman Foundation and was conducted in RAND Health and the Kauffman-RAND Institute for Entrepreneurship Public Policy (KRI). KRI is housed within the RAND Institute for Civil Justice (ICJ). Both RAND Health and RAND ICJ are divisions of the RAND Corporation.
This report is part of the RAND Corporation Occasional paper series. RAND occasional papers may include an informed perspective on a timely policy issue, a discussion of new research methodologies, essays, a paper presented at a conference, or a summary of work in progress. All RAND occasional papers undergo rigorous peer review to help ensure that they meet high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.